Rigel Pharmaceuticals (RIGL) Revenue (2010 - 2026)
Rigel Pharmaceuticals' quarterly Revenue came in at $58.8 million in Q1 2026, up 10.28% year-on-year from $53.3 million in Q1 2025, and down 15.74% quarter-over-quarter from $69.8 million in Q4 2025.
Rigel Pharmaceuticals has reported Revenue for 16 years, with the latest figure at $58.8 million in Q1 2026.
- For the quarter ending Q1 2026, Revenue rose 10.28% year-over-year to $58.8 million; the trailing twelve-month figure through Mar 2026 stood at $299.8 million (up 47.61% YoY), and the FY2025 full-year result was $294.3 million, up 64.15% from the prior year.
- Revenue for Q1 2026 stood at $58.8 million, down from $69.8 million in the prior quarter.
- The five-year high for Revenue was $101.7 million in Q2 2025, with the low at $16.7 million in Q1 2022.
- Average Revenue over 5 years is $45.3 million, with a median of $36.8 million recorded in 2024.
- Year-over-year, Revenue tumbled 79.34% in 2022 and jumped 176.01% in 2025.
- Tracing RIGL's Revenue over 5 years: stood at $51.3 million in 2022, then slumped by 30.2% to $35.8 million in 2023, then surged by 60.92% to $57.6 million in 2024, then climbed by 21.19% to $69.8 million in 2025, then declined by 15.74% to $58.8 million in 2026.
- The last three Revenue figures came in at $58.8 million (Q1 2026), $69.8 million (Q4 2025), and $69.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 306.30 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 2.99 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 3.61 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.17 Bn |
| 10 | Rigel Pharmaceuticals | 551.62 Mn | 404.94 Mn | 54.21 Mn | 58.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 58.82 Mn |
| Dec 31, 2025 | 69.80 Mn |
| Sep 30, 2025 | 69.46 Mn |
| Jun 30, 2025 | 101.69 Mn |
| Mar 31, 2025 | 53.33 Mn |
| Dec 31, 2024 | 57.60 Mn |
| Sep 30, 2024 | 55.31 Mn |
| Jun 30, 2024 | 36.84 Mn |
| Mar 31, 2024 | 29.53 Mn |
| Dec 31, 2023 | 35.79 Mn |
| Sep 30, 2023 | 28.13 Mn |
| Jun 30, 2023 | 26.89 Mn |
| Mar 31, 2023 | 26.07 Mn |
| Dec 31, 2022 | 51.28 Mn |
| Sep 30, 2022 | 22.41 Mn |
| Jun 30, 2022 | 29.82 Mn |
| Mar 31, 2022 | 16.74 Mn |
| Dec 31, 2021 | 20.41 Mn |
| Sep 30, 2021 | 21.54 Mn |
| Jun 30, 2021 | 26.27 Mn |
| Mar 31, 2021 | 81.02 Mn |
| Dec 31, 2020 | 18.45 Mn |
| Sep 30, 2020 | 18.39 Mn |
| Jun 30, 2020 | 16.02 Mn |
| Mar 31, 2020 | 55.76 Mn |
| Dec 31, 2019 | 15.40 Mn |
| Sep 30, 2019 | 20.86 Mn |
| Jun 30, 2019 | 10.41 Mn |
| Mar 31, 2019 | 12.62 Mn |
| Dec 31, 2018 | 37.86 Mn |
| Sep 30, 2018 | 4.87 Mn |
| Jun 30, 2018 | 1.79 Mn |
| Dec 31, 2017 | -4.48 Mn |
| Sep 30, 2017 | 900,000.00 |
| Mar 31, 2017 | 3.58 Mn |
| Dec 31, 2016 | 3.00 Mn |
| Sep 30, 2016 | 3.76 Mn |
| Jun 30, 2016 | 8.59 Mn |
| Mar 31, 2016 | 5.03 Mn |
| Dec 31, 2015 | 8.54 Mn |
| Sep 30, 2015 | 13.00 Mn |
| Jun 30, 2015 | 5.18 Mn |
| Mar 31, 2015 | 2.18 Mn |
| Dec 31, 2013 | 5.75 Mn |
| Jun 30, 2013 | 1.40 Mn |
| Jun 30, 2012 | 1.50 Mn |
| Mar 31, 2012 | 750,000.00 |
| Sep 30, 2011 | 4.36 Mn |
| Jun 30, 2011 | 395,000.00 |
| Sep 30, 2010 | 72.28 Mn |
| Jun 30, 2010 | 49.46 Mn |